Dr. Joseph P. Uberti, MD PHD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Wayne State University School of Medicine (1978)
- Years since graduation
- 48
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 180
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1978Medical school: Wayne State University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MI license 4301049451 -
Internal Medicine Physician
MI license 4301049451 -
Medical Oncology Physician
MI license 4301049451
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Henry Ford Health St John Hospital Detroit, MI
- Karmanos Cancer Center Detroit, MI
Medical groups
- University Physician Group (403 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 180
- Services billed
- 850
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 374 | 119 |
| Established patient office or other outpatient visit, 40-54 minutes | 58 | 39 |
| Established patient office or other outpatient visit, 20-29 minutes | 50 | 37 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 49 | 11 |
| New patient office or other outpatient visit, 45-59 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Detroit, MI | 23 |
| Magnesium Sulfate | 22 |
| Zarxio (filgrastim-sndz) | 17 |
| Montelukast Sodium Other prescribers in Detroit, MI | 15 |
| Tacrolimus Other prescribers in Detroit, MI | 14 |
| Folic Acid Other prescribers in Detroit, MI | 13 |
| Tamsulosin Hcl Other prescribers in Detroit, MI | 13 |
| Revlimid (lenalidomide) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $23.10 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $23.10 |
|---|
| Education | $23.10 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP May 21, 2025 | Education in-kind Company’s descriptionJournal Article | $23.10 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 5 companies. The companies reported $216,839 in research payments for these studies, mostly to the institutions running them.
- A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)
Incyte Corporation - AGAVE-201, a phase 2, open-label, randomized, multicenter study to evaluate the efficacy, safety and tolerability of axatilimab at 3 different doses in patients with recurrent or refractory active chronic graft versus…
Syndax Pharmaceuticals, Inc. - A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
Sanofi US Services Inc. · Active, not recruiting · NCT06143891 - A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic…
National Marrow Donor Program - A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
AbbVie Inc. · Terminated · NCT04161885 - A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Haploidentical Related, Partially HLA-Mismatched, or Matched Unrelated Bone Marrow for Newly Diagnosed Patients with Severe Aplastic Anemia
National Marrow Donor Program - Facilitating Activation of Study Trials (FAST)
National Marrow Donor Program - A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.